Gene Therapies Dominate New Crop Of EU PRIME Recipients
Among the six new investigational products to make it onto the European Medicines Agency’s priority medicines scheme, five were gene therapies.
You may also be interested in...
Pipeline Watch: Liver Disease Candidates Dominate
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Winners And Losers: A Deep-Dive Into The EMA’s PRIME Scheme
Nine of the 70 medicines for unmet medical needs that have to date won a place on the European Medicines Agency’s PRIME scheme are now approved for sale in the EU, and two more approvals are expected soon. Meanwhile, most applications for a "priority medicine" designation are still missing the mark.
EMA Recommends Revoking EU Approval For Novartis’s Sickle Cell Disease Drug
The results of a Phase III study did not confirm the benefits previously seen with Adakveo, the European Medicines Agency said.